Key result
Serotonin reuptake inhibitor exposure did not influence mean pulmonary artery pressure compared to controls in patients without pulmonary hypertension.
Why the study?
Does serotonin reuptake inhibitor treatment increase mean pulmonary artery pressure in patients without pulmonary hypertension?
Observational (n=16)
No
Does serotonin reuptake inhibitor treatment increase mean pulmonary artery pressure in patients without pulmonary hypertension?
Treatment with serotonin reuptake inhibitors does not significantly alter pulmonary hemodynamics or induce pulmonary hypertension in adult patients without pre-existing pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Supports SRI safety on pulmonary hemodynamics in non-PH patients; leaves open causal effects and generalizability pending prospective trials.
BACKGROUND: Serotonin promotes pulmonary arterial vasoconstriction and pulmonary arterial smooth muscle cell proliferation, thereby having the potential to increase pulmonary arterial blood pressure. Although serotonin reuptake inhibitors (SRIs) might inhibit further deterioration in patients with manifest pulmonary arterial hypertension, they may induce pulmonary hypertension in healthy newborns after fetal exposure. As it is unclear whether treatment with SRIs affects pulmonary hemodynamics in adults without pulmonary hypertension, the aim of the present study was to investigate the effect of SRIs on pulmonary hemodynamics in such subjects. METHODS: Sixteen patients with stable angina pectoris scheduled for first time coronary artery bypass grafting were included in the study. Of these 8 were currently treated with an SRI (the SRI group) and 8 were not (the control group). Pulmonary arterial pressures were measured before induction of anesthesia by means of a pulmonary artery catheter. Serotonin transporter and 5-HT(2A) receptor gene polymorphisms and platelet 5-HT(2A) receptor expression were studied to elucidate their possible role as modifying factors. RESULTS: No patients in any of the groups had pulmonary arterial hypertension. Mean pulmonary artery pressure was 15.0 mmHg in the SRI group and 14.5 mmHg in the control group (P = 0.50; 95% confidence interval for the difference, -2.9 to +3.9 mmHg). Neither were there any significant differences between the groups for any of the other hemodynamic variables studied. The various gene polymorphisms and the extent of platelet 5-HT(2A) receptor expression did not influence the hemodynamic variables. CONCLUSIONS: SRI treatment did not significantly influence pulmonary hemodynamics in patients without pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Pleym (2011) conducted an observational in Stable angina pectoris (n=16). Serotonin reuptake inhibitors vs. No serotonin reuptake inhibitor treatment was evaluated on Mean pulmonary artery pressure (MPAP) (MD 0.5, 95% CI -2.9 to 3.9, p=0.50). Serotonin reuptake inhibitor exposure did not influence mean pulmonary artery pressure compared to controls in patients without pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: